Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to filing requirements for the past 90 days. ~~YES~~ Yes☒ NO ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ~~YES~~ Yes☒ NO ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of outstanding shares of the registrant’s common stock, par value $0.001 per share, was ~~6,134,719~~8,704,723 as of ~~May 7,~~November 8, 2021.

	March 31,			December 31,			September 30,			December 31,
	2021			2020			2021			2020
	(unaudited)						(unaudited)
ASSETS
Current assets
Cash and cash equivalents	$	9,529		$	5,889		$	9,820		$	5,889
Short-term investments		1,610			—			8,213			—
Accounts receivable, net		375			701			749			701
Inventories		862			599			1,153			599
Prepaid expenses and other		534			668			694			668
Total current assets		12,910			7,857			20,629			7,857
Long-term investments								3,203			—
Property and equipment, net		105			121			89			121
Right-of-use lease asset, net		254			303			155			303
Other		18			17			18			17
Total assets	$	13,287		$	8,298		$	24,094		$	8,298
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable	$	81		$	76		$	144		$	76
Accrued expenses and other								1,562			1,300
Deferred revenue		15			15			162			15
Short-term lease liability		201			201			163			201
PPP note payable, current		434			244			—			244
Accrued expenses and other		1,291			1,300
Total current liabilities		2,022			1,836			2,031			1,836
Convertible notes payable		—			3,092			—			3,092
PPP note payable		145			335			—			335
Long-term lease liability		57			103			—			103
Total liabilities		2,224			5,366			2,031			5,366
Commitments and contingencies (Note 4)
Commitments and contingencies (Note 5)
Stockholders’ equity
Preferred stock, $0.01 par value; 20,000 shares authorized; none issued and outstanding		—			—
Common stock, $0.001 par value; 120,000 shares authorized; 6,134 shares and 3,554 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively		6			3
Preferred stock, $0.01 par value; 20,000 shares authorized; NaN issued and outstanding								—			—
Common stock, $0.001 par value; 120,000 shares authorized; 8,686 shares and 3,554 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively								9			3
Additional paid-in capital		255,046			245,548			268,967			245,548
Accumulated other comprehensive loss		(1	)		—			(6	)		—
Accumulated deficit		(243,988	)		(242,619	)		(246,907	)		(242,619	)
Total stockholders’ equity		11,063			2,932			22,063			2,932
Total liabilities and stockholders’ equity	$	13,287		$	8,298		$	24,094		$	8,298

The accompanying notes are an integral part of these condensed consolidated financial statements.

	Three Months Ended						Three Months Ended						Nine Months Ended
	March 31,						September 30,						September 30,
	2021			2020			2021			2020			2021			2020
Net revenue
Product	$	1,178		$	1,068		$	1,210		$	1,803		$	3,405		$	4,550
Royalty and other		160			192			127			168			438			649
Total net revenue		1,338			1,260			1,337			1,971			3,843			5,199
Cost of net revenue		495			530			376			677			1,315			1,811
Gross profit		843			730			961			1,294			2,528			3,388
Operating expenses
Research and development		1,159			961			1,281			972			3,662			2,918
Selling, general and administrative		1,071			1,135			1,398			955			3,756			3,054
Total operating expenses		2,230			2,096			2,679			1,927			7,418			5,972
Loss from operations		(1,387	)		(1,366	)		(1,718	)		(633	)		(4,890	)		(2,584	)
Interest expense		(30	)		(55	)		—			(70	)		(30	)		(181	)
Other income, net		48			16
Other income (expense), net								4			(4	)		632			14
Net loss	$	(1,369	)	$	(1,405	)		(1,714	)		(707	)		(4,288	)		(2,751	)
Deemed dividend for warrant exercise price adjustment								—			—			—			(392	)
Net loss attributable to common stockholders							$	(1,714	)	$	(707	)	$	(4,288	)	$	(3,143	)

Other comprehensive loss, net of tax:
Net unrealized loss on available-for-sale securities		(1	)		—			(2	)		—			(6	)		—
Comprehensive loss	$	(1,370	)	$	(1,405	)	$	(1,716	)	$	(707	)	$	(4,294	)	$	(2,751	)

Net loss per share

Net loss per share attributable to common stockholders
Basic and diluted	$	(0.28	)	$	(0.61	)	$	(0.20	)	$	(0.20	)	$	(0.63	)	$	(1.03	)

Shares used in computing net loss per share
Basic and diluted		4,862			2,295			8,676			3,546			6,812			3,037

The accompanying notes are an integral part of these condensed consolidated financial statements.

								Accumulated																Accumulated
					Additional			Other													Additional			Other
	Common Stock				Paid-In			Comprehensive			Accumulated						Common Stock				Paid-In			Comprehensive			Accumulated
	Shares		Amount		Capital			Loss			Deficit			Total			Shares		Amount		Capital			Loss			Deficit			Total
Balance as of December 31, 2020		3,554	$	3	$	245,548			—		$	(242,619	)	$	2,932			3,554	$	3	$	245,548		$	—		$	(242,619	)	$	2,932
Issuance of common stock under stock plan, net		16		—		(2	)		—			—			(2	)		16		—		(2	)		—			—			(2	)
Exercise of warrants		1,033		1		2,477			—			—			2,478			1,033		1		2,477			—			—			2,478
Issuance of common stock for payment of accrued interest		43		—		140			—			—			140			43		—		140			—			—			140
Sale of common stock, net of placement costs		1,488		2		6,815			—			—			6,817			1,488		2		6,815			—			—			6,817
Stock-based compensation		—		—		68			—			—			68			—		—		68			—			—			68
Unrealized loss on available-for-sale investments		—		—		—			(1	)		—			(1	)		—		—		—			(1	)		—			(1	)
Net loss		—		—		—			—			(1,369	)		(1,369	)		—		—		—			—			(1,369	)		(1,369	)
Balance as of March 31, 2021		6,134	$	6	$	255,046		$	(1	)	$	(243,988	)	$	11,063			6,134	$	6	$	255,046		$	(1	)	$	(243,988	)	$	11,063

Issuance of common stock under stock plan, net																		2		—		—			—			—			—
Exercise of warrants																		706		1		1,695			—			—			1,696
Sale of common stock, net of placement costs																		1,818		1		11,968			—			—			11,969
Stock-based compensation																		—		—		97			—			—			97
Unrealized loss on available-for-sale investments																		—		—		—			(3	)		—			(3	)
Net loss																		—		—		—			—			(1,205	)		(1,205	)
Balance as of June 30, 2021																		8,660	$	8	$	268,806		$	(4	)	$	(245,193	)	$	23,617
Issuance of common stock under stock plan, net																		20		—		(3	)		—			—			(3	)
Exercise of warrants																		6		1		14			—			—			15
Stock-based compensation																		—		—		150			—			—			150
Unrealized loss on available-for-sale investments																		—		—		—			(2	)		—			(2	)
Net loss																		—		—		—			—			(1,714	)		(1,714	)
Balance as of September 30, 2021																		8,686	$	9	$	268,967		$	(6	)	$	(246,907	)	$	22,063

								Accumulated																Accumulated
					Additional			Other													Additional			Other
	Common Stock				Paid-In			Comprehensive			Accumulated						Common Stock				Paid-In			Comprehensive			Accumulated
	Shares		Amount		Capital			Loss			Deficit			Total			Shares		Amount		Capital			Loss			Deficit			Total
Balance as of December 31, 2019		2,179	$	2	$	243,281			—		$	(238,447	)	$	4,836			2,179	$	2	$	243,281		$	—		$	(238,447	)	$	4,836
Issuance of common stock for release of awards		20		—		(1	)		—			—			(1	)		20		—		(1	)		—			—			(1	)
Exercise of pre-funded warrants		116		—		2			—			—			2			116		—		2			—			—			2
Stock-based compensation		—		—		68			—			—			68			—		—		68			—			—			68
Net loss		—		—		—			—			(1,405	)		(1,405	)		—		—		—			—			(1,405	)		(1,405	)
Balance as of March 31, 2020		2,315	$	2	$	243,350		$	—		$	(239,852	)	$	3,500			2,315	$	2	$	243,350		$	—		$	(239,852	)	$	3,500
Issuance of common stock for release of awards																		1		—		—			—			—			—
Sale of common stock, net of placement costs																		1,218		1		1,618			—			—			1,619
Deemed dividend for warrant exercise price adjustment																		—		—		392			—			(392	)		—
Stock-based compensation																		—		—		66			—			—			66
Net loss																		—		—		—			—			(639	)		(639	)
Balance as of June 30, 2020																		3,534	$	3	$	245,426		$	—		$	(240,883	)	$	4,546
Issuance of common stock for release of awards																		19		—		(1	)		—			—			(1	)
Stock-based compensation																		—		—		63			—			—			63
Net loss																		—		—		—			—			(707	)		(707	)
Balance as of September 30, 2020																		3,553	$	3	$	245,488		$	-		$	(241,590	)	$	3,901

The accompanying notes are an integral part of these condensed consolidated financial statements.

	Three Months Ended						Nine Months Ended
	March 31,						September 30,
	2021			2020			2021			2020
Cash flows from operating activities:
Net loss	$	(1,369	)	$	(1,405	)	$	(4,288	)	$	(2,751	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		18			41			51			121
Stock-based compensation		68			68			315			197
Accrued interest		30			55			30			181
Amortization of lease right-of-use asset		49			47			147			—
Change in operating lease liability		(46	)		(50	)		(141	)		(5	)
Gain on settlement of convertible notes payable and accrued interest, net		(48	)		—			(48	)		—
Gain on extinguishment of PPP Note								(579	)		—
Changes in assets and liabilities:
Accounts receivable		325			636			(48	)		385
Inventories		(263	)		(137	)		(554	)		255
Prepaid expenses and other assets		134			(35	)		(26	)		174
Accounts payable		5			(111	)		68			(138	)
Deferred revenue and other liabilities		84			183			502			(35	)
Net cash used in operating activities		(1,013	)		(708	)		(4,571	)		(1,616	)
Cash flows from investing activities:
Purchases of property and equipment		(2	)		(6	)		(19	)		(14	)
Proceeds from maturities of short-term investments		—			300			1,250			300
Purchases of short-term investments		(1,611	)		—
Purchases of investments								(12,672	)		—
Net cash provided by (used in) investing activities		(1,613	)		294			(11,441	)		286
Cash flows from financing activities:
Proceeds from sale of common stock, net		6,817			—			18,786			1,619
Proceeds from exercise of common stock warrants		2,478			2			4,189			2
Repayment of convertible notes payable		(3,027	)		—			(3,027	)		—
Proceeds from PPP note								—			579
Taxes paid to net share settle equity awards		(2	)		(1	)		(5	)		(2	)
Net cash provided by financing activities		6,266			1			19,943			2,198
Net increase (decrease) in cash and cash equivalents		3,640			(413	)
Net increase in cash and cash equivalents								3,931			868
Cash and cash equivalents at beginning of period		5,889			6,053			5,889			6,053
Cash and cash equivalents at end of period	$	9,529		$	5,640		$	9,820		$	6,921
Supplemental disclosure:
Issuance of convertible notes in settlement of accrued interest	$	—		$	112		$	—		$	234
Settlement of accrued interest through issuance of common shares	$	123		$	—		$	123		$	—
Fair value of warrant exercise price adjustment considered as deemed dividend							$	—		$	392

The accompanying notes are an integral part of these condensed consolidated financial statements.

MoSys, Inc. (the Company) was incorporated in California in 1991 and reincorporated in 2000 in Delaware. The Company provides both integrated circuits (ICs) and intellectual property (IP) solutions that enable fast, intelligent data access and decision making for a wide range of markets. The Company’s primary product line is marketed under the Accelerator Engine name and includes the Bandwidth Engine IC products, which integrate the Company’s proprietary, 1T-SRAM high-density embedded memory and a highly-efficient serial interface protocol resulting in a monolithic memory IC solution optimized for memory bandwidth and transaction access performance. In 2020, the Company began offering for license the first of its Virtual Accelerator Engine ~~products~~IP solutions which ~~consist of~~comprise software, firmware and related IP. ~~This new product line~~The Company’s VAE IP solutions will include multiple function accelerator platform products, which target specific application functions, such as packet classifications, and ~~will~~ use a common software interface to allow performance scalability over multiple hardware environments.

The accompanying condensed consolidated financial statements of the Company have been prepared without audit.

The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited consolidated financial statements at that date. Certain information and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (GAAP) have been condensed or omitted in accordance with these rules and regulations of the Securities and Exchange Commission (SEC). The information in this report should be read in conjunction with the Company’s consolidated financial statements and notes thereto included in its most recent annual report on Form 10-K filed with the SEC.

In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company’s financial position, results of operations and cash flows for the interim periods presented. The operating results for the three and nine months ended ~~March 31,~~September 30, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021 or for any other future period.

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation. The Company’s fiscal year ends on December 31 of each calendar year.

The Company is subject to risks from, among other things, competition associated with the industry in general, other risks associated with financing, liquidity requirements, rapidly changing customer requirements, limited operating history and the volatility of public markets.

The global outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency by the U.S. government in March 2020. This has negatively affected the U.S. and global economy, disrupted global supply chains, significantly restricted travel and transportation, resulted in mandated closures and orders to “shelter-in-place” and created significant disruption of the financial markets. The full extent of the COVID-19 impact on the Company’s operational and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions taken by U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of the Company’s control, and cannot be predicted.

The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at

the date of the financial statements and the reported amounts of revenues and expenses recognized during the reported period. Actual results could differ from those estimates.

The Company has invested its excess cash in money market accounts, certificates of deposit, commercial paper, corporate debt, government-sponsored enterprise bonds and municipal bonds and considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. Investments with original maturities greater than three months and remaining maturities less than one year are classified as short-term investments. Investments with remaining maturities greater than one year are classified as long-term investments. Management generally determines the appropriate classification of securities at the time of purchase. All securities are classified as available-for-sale. The Company’s available-for-sale short-term investments are carried at fair value, with the unrealized holding gains and losses reported in accumulated other comprehensive income. Realized gains and losses and declines in the value judged to be other than temporary are included in the other income, net line item in the condensed consolidated statements of operations and comprehensive loss. The cost of securities sold is based on the specific identification method.

The Company measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels:

Level 1— Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date.

Level 2— Pricing is provided by third party sources of market information obtained through the Company’s investment advisors, rather than models. The Company does not adjust for, or apply, any additional assumptions or estimates to the pricing information it receives from advisors. The Company’s Level 2 securities may include cash equivalents and available-for-sale securities, which consist primarily of certificates of deposit, corporate debt, and government agency and municipal debt securities from issuers with high-quality credit ratings. The Company’s investment advisors obtain pricing data from independent sources, such as Standard & Poor’s, Bloomberg and Interactive Data Corporation, and rely on comparable pricing of other securities because the Level 2 securities are not actively traded and have fewer observable transactions. The Company considers this the most reliable information available for the valuation of the securities.

Level 3— Unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment are used to measure fair value. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions. The determination of fair value for Level 3 investments and other financial instruments involves the most management judgment and subjectivity.

The Company establishes an allowance for doubtful accounts to ensure that its trade receivables balances are not overstated due to uncollectibility. The Company performs ongoing customer credit evaluations within the context of the industry in which it operates and generally does not require collateral from its customers. A specific allowance of up to 100% of the invoice value is provided for any problematic customer balances. Delinquent account balances are written off after management has determined that the likelihood of collection is remote. The Company grants credit only to customers deemed creditworthy in the judgment of management. ~~The~~There was 0 allowance for doubtful accounts ~~was $41,000~~ at ~~March 31,~~either September 30, 2021 ~~and~~or December 31, 2020.

The Company values its inventories at the lower of cost, which approximates actual cost on a first-in, first-out basis, or net realizable value. The Company records inventory reserves for estimated obsolescence or unmarketable inventories based upon assumptions about future demand and market conditions. Once a reserve is established, it is maintained until the product to which it relates is sold or otherwise disposed of. If actual market conditions are less favorable than those expected by management, additional adjustment to inventory valuation may be required. Charges for obsolete and slow-moving inventories are recorded based upon an analysis of specific identification of obsolete inventory items and

quantification of slow moving inventory items. The Company recorded no0 material write-downs of inventory during the ~~three~~nine months ended ~~March 31,~~September 30, 2021 and recorded write-downs of $0.1 million for the ~~year~~nine months ended ~~December 31,~~September 30, 2020.

The Company generates revenue primarily from sales of IC products and licensing of its IP. Revenues are recognized when control is transferred to customers in amounts that reflect the consideration the Company expects to be entitled to receive in exchange for those goods. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied.

Revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied.

The majority of the Company’s contracts have a single performance obligation to transfer products. Accordingly, the Company recognizes revenue when title and risk of loss have been transferred to the customer, generally at the time of shipment of products. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products and is generally based upon a negotiated, formula, list or fixed price. The Company sells its products both directly to customers and through distributors generally under agreements with payment terms typically less than 60 days.

The Company’s licensing contracts typically provide for royalties based on the licensee’s use of the Company’s memory technology in its currently shipping commercial products. The Company estimates its royalty revenue in the calendar quarter in which the licensee uses the licensed technology. Payments are generally received in the subsequent quarter.

The Company’s contract liabilities consist of advance customer payments and deferred revenue. The Company classifies advance customer payments and deferred revenue as current or non-current based on the timing of when the Company expects to recognize revenue.

During the ~~three~~nine months ended ~~March 31,~~September 30, 2021, the Company recognized no0 revenue that had been included in deferred revenue as of December 31, 2020.

Cost of net revenue consists primarily of direct and indirect costs of IC product sales and engineering personnel costs directly related to maintenance and support services specified in licensing agreements. Maintenance and support typically ~~include~~includes engineering support to assist in the commencement of production of a licensee’s products.

As of ~~March 31,~~September 30, 2021, the Company had the following warrants outstanding (share amounts in thousands):


Warrant Type	Number of Shares		Exercise Price		Expiration
Type						Number of Shares		Exercise Price		Expiration
Common stock		33	$	47.00	January 2023		33	$	47.00	January 2023
Common stock		813	$	2.40	October 2023		101	$	2.40	October 2023

Basic net income (loss) per share is computed by dividing net income (loss) for the period by the weighted-average number of shares of common stock outstanding during the period. Diluted net income (loss) per share gives effect to all potentially dilutive shares of common stock outstanding during the period. Potentially dilutive shares of common stock consist of incremental shares of common stock issuable upon the exercise of stock options, vesting of stock awards and shares issuable in conjunction with convertible notes.

The following table sets forth securities outstanding that were excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive (in thousands):


	March 31,				September 30,
	2021		2020		2021		2020
Options outstanding to purchase common stock		159		161		159		160
Unvested restricted common stock units		58		82		94		60
Convertible notes		-		254		—		271
Warrants		846		1,879		134		1,879
Total		1,063		2,376		387		2,370

On September 14, 2021, the Company and its newly formed subsidiaries, 2864552 Ontario Inc. (Callco) and 2864555 Ontario Inc. (Canco), both corporations existing under the laws of the province of Ontario, entered into an Arrangement Agreement (the Agreement) with Peraso Technologies Inc., a corporation existing under the laws of the province of Ontario (Peraso). Under the Agreement, the Company, indirectly through Canco, is to acquire all of the issued and outstanding common shares of Peraso (Peraso Shares), including those Peraso Shares to be issued in connection with the conversion or exchange of secured convertible debentures of Peraso and common share purchase warrants of Peraso, as applicable, by way of a statutory plan of arrangement (the Arrangement) under the Business Corporations Act (Ontario) (the OBCA), on and subject to the terms and conditions of the Agreement.

The Agreement provides that the Peraso stockholders may elect to receive either shares of the Company’s common stock or shares of the capital stock of Canco (the Exchangeable Shares) in exchange for such holder’s Peraso Shares, in each case based on an exchange ratio (the Exchange Ratio) to be determined based on the number of Peraso Shares and Company’s common stock outstanding as of immediately prior to the effective time of the Arrangement (the “Effective Time”). Pursuant to the terms of the Agreement, at the Effective Time, the Company shall hold an aggregate of 1,815,445 Exchangeable Shares and its common stock (collectively, the Earnout Shares). Such Earnout Shares shall be escrowed pursuant to the terms of an escrow agreement on a pro rata basis from the aggregate consideration to be received by the Peraso stockholders, subject to the offset by the Company for any losses in accordance with the Agreement. Such Earnout Shares shall be released, subject to any offset claim, upon the satisfaction of the earlier of: (a) any date following the first anniversary of the Effective Time and prior to the third anniversary of the Effective Time where the volume weighted average price of the Common Stock for any 20 trading days within a period of 30 consecutive trading days is at least $8.57 per share, subject to adjustment for stock splits or other similar transaction; (b) the date of any sale of all or substantially all of the assets or shares of the Company; or (c) the date of any bankruptcy, insolvency, restructuring, receivership, administration, wind-up, liquidation, dissolution, or similar event involving the Company.

Following the Effective Time, each Exchangeable Share will be exchangeable by the holder for one share of Common Stock (subject to customary adjustments for stock splits or other reorganizations). In addition, the Company may require all outstanding Exchangeable Shares to be exchanged upon the occurrence of certain events and at any time following the seventh anniversary of the closing of the Arrangement. While outstanding, holders of Exchangeable Shares will be entitled to cast votes on matters for which holders of Common Stock are entitled to vote and will be entitled to receive dividends economically equivalent to the dividends declared by the Company with respect to the Common Stock. Eligibility to receive Exchangeable Shares will be subject to certain Canadian residency restrictions and tax statuses.

The Agreement also provides that Peraso stock options, which are exercisable for Peraso Shares, will be replaced with an option to acquire Common Stock to be issued by the Company in consideration for cancellation of the Peraso

options and exercisable for shares of Common Stock after the Effective Time, in each case with adjustments based on the Exchange Ratio. The exact number of shares of Common Stock that will be issued pursuant to the Arrangement will be determined at the Effective Time in accordance with the Exchange Ratio.

Immediately following the Effective Time, based on the Exchange Ratio, the former stockholders of Peraso are anticipated to own approximately 61% of the economic and voting interest of the combined company with the Company’s current stockholders holding the remaining 39% economic and voting interest, as calculated on a fully-diluted basis and including the Earnout Shares.

The consummation of the Arrangement is subject to certain closing conditions precedent, including both the Company’s and Peraso’s stockholders approval of the Agreement and transactions contemplated therein; the order of the Ontario Superior Court of Justice (Commercial List) granted pursuant to Section 182(5) of the Business Corporations Act (Ontario); all regulatory approvals; the continuing listing of the Common Stock on Nasdaq; and other customary closing conditions.

The transaction is expected to close in the fourth calendar quarter of 2021 and to be implemented by way of an arrangement under the OBCA. The Agreement provides for customary representations, warranties and covenants, including covenants of each party to (i) subject to certain exceptions, carry on its business in the ordinary course of business consistent with past practice during the period between the execution of the Agreement and the Effective Time and (ii) not solicit any alternate transactions or, subject to certain exceptions, to engage in any discussions or negotiations with respect thereto. Subject to certain terms and conditions, the Agreement may be terminated if the Effective Time does not occur on or before November 30, 2021, subject to certain automatic extensions. The Agreement may also be terminated by either party, if the respective stockholders’ approval is not obtained, in the event of material adverse effect, or a superior proposal in connection with an alternative acquisition. The Agreement subjects the parties to certain termination payment obligations. If the Agreement is terminated because of the failure to obtain stockholders’ approval, the party that failed to obtain such approval will be obligated to pay a fee of $750,000 to the other party. If the Agreement is terminated by either party as a result of obtaining a superior proposal from a third party, breach of non-solicitation covenants of the Agreement, or because either party’s board of directors fails to unanimously recommend to proceed with the Arrangement or withdraws its recommendation, the breaching party will be required to pay a termination fee of $3,500,000.

The estimated fair values of financial instruments outstanding were (in thousands):

	March 31, 2021									September 30, 2021
			Unrealized		Unrealized			Fair				Unrealized		Unrealized			Fair
	Cost		Gains		Losses			Value		Cost		Gains		Losses			Value
Cash and cash equivalents	$	9,529	$	—	$	—		$	9,529	$	9,820	$	0	$	0		$	9,820
Short-term investments		1,611		—		(1	)		1,610		8,216		0		(3	)		8,213
Long-term investments											3,206		0		(3	)		3,203
	$	11,140	$	—	$	(1	)	$	11,139	$	21,242	$	0	$	(6	)	$	21,236

The following table represents the Company’s fair value hierarchy for its financial assets (cash equivalents and investments) (in thousands):

	March 31, 2021								September 30, 2021
	Fair Value		Level 1		Level 2		Level 3		Fair Value		Level 1		Level 2		Level 3
Money market funds	$	7,276	$	7,276	$	—	$	—	$	7,948	$	7,948	$	—	$	—
Corporate notes and commercial paper(1)	$	1,610	$	—	$	1,610	$	—	$	11,916	$	—	$	11,916	$	—
									$	19,864	$	7,948	$	11,916	$	—

(1) Includes $0.5 million in cash and cash equivalents on the accompanying condensed consolidated balance sheet due to original maturities of less than three months. There were no0 transfers in or out of Level 1 and Level 2 securities during the ~~three~~nine months ended ~~March 31,~~September 30, 2021 or 2020.

	March 31,		December 31,		September 30,		December 31,
	2021		2020		2021		2020
	(in thousands)				(in thousands)
Inventories:
Work-in-process	$	654	$	414	$	707	$	414
Finished goods		208		185		446		185
	$	862	$	599	$	1,153	$	599

In the ordinary course of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties from any losses incurred relating to breach of representations and warranties, failure to perform certain covenants, or claims and losses arising from certain events as outlined within the particular contract, which may include, for example, losses arising from litigation or claims relating to past performance. Such indemnification clauses may not be subject to maximum loss clauses. The Company has also entered into indemnification agreements with its officers and directors. No material amounts were reflected in the Company’s condensed consolidated financial statements for the ~~three~~nine months ended ~~March 31,~~September 30, 2021 or 2020 related to these indemnifications.

The Company has not estimated the maximum potential amount of indemnification liability under these agreements due to the limited history of prior claims and the unique facts and circumstances applicable to each particular agreement. To date, the Company has not made any material payments related to these indemnification agreements.

The Company is not a party to any legal proceeding that the Company believes is likely to have a material adverse effect on its condensed consolidated financial position or results of operations. From time to time the Company may be subject to legal proceedings and claims in the ordinary course of business. These claims, even if not meritorious, could result in the expenditure of significant financial resources and diversion of management efforts.

Note 5. 6. Business Segments, Concentration of Credit Risk and Significant Customers

The Company operates in ~~one~~1 business segment and uses ~~one~~1 measurement of profitability for its business. Net revenue is attributed to the United States and to all foreign countries based on the geographical location of the customer.

The Company recognized revenue from shipment of product and licensing of its technologies to customers by geographical location as follows (in thousands):

	Three Months Ended		Three Months Ended		Nine Months Ended
	March 31,		September 30,		September 30,
	2021	2020	2021	2020	2021	2020
Customer A	38%	26%	31%	24%	35%	26%
Customer B	20%	19%	21%	17%	14%	11%
Customer C	18%	14%	20%	11%	25%	*
Customer D	*%	12%	14%	*	*	*
Customer E	*%	11%

~~Three~~NaN customers accounted for ~~74%~~88% of accounts receivable as of ~~March 31,~~September 30, 2021. ~~Three~~NaN customers accounted for 86% of accounts receivable as of December 31, 2020.

The Company determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the Company’s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to affect taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that all or a portion of the deferred tax assets will not be realized.

The Company files U.S. federal and state and foreign income tax returns in jurisdictions with varying statutes of limitations. All tax returns from ~~2014~~2015 to ~~2019~~2020 may be subject to examination by the Internal Revenue Service, California and other states. Returns filed in foreign jurisdictions may be subject to examination for the years ~~2010~~2011 to ~~2019.~~2020. As of ~~March 31,~~September 30, 2021, the Company has not recorded any liability for unrecognized tax benefits related to uncertain tax positions.

In 2010, the Company adopted the 2010 Equity Incentive Plan and later amended it in 2014, 2017 and 2018 (the Amended 2010 Plan). The Amended 2010 Plan was terminated in August 2019 and remains in effect as to outstanding equity awards granted prior to the date of expiration. As of ~~March 31,~~September 30, 2021, no new awards may be made under the Amended 2010 Plan, and equity awards for approximately ~~57,858~~94,224 shares were outstanding.

In August 2019, the Company’s stockholders approved the 2019 Stock Incentive Plan (the 2019 Plan), and it replaced the Amended 2010 Plan. The 2019 Plan authorizes the board of directors or the compensation committee of the board of directors to grant a broad range of awards including stock options, stock appreciation rights, restricted stock, performance-based awards, and restricted stock units. Under the 2019 Plan, 182,500 shares have been reserved for issuance. The 2019 Plan provides for annual option grants or other awards to the Company’s non-employee directors to acquire up to 2,000 shares and for a one-time grant of an option or other award to a non-employee director to acquire up to 6,000 shares upon his or her initial appointment or election to the board of directors.

Under the 2019 Plan, the term of all incentive stock options granted to a person who, at the time of grant, owns stock representing more than 10% of the voting power of all classes of the Company’s stock may not exceed five years. The exercise price of stock options granted under the 2019 Plan must be at least equal to the fair market value of the shares on the date of grant. Generally, awards under the 2019 Plan will vest over a three to four-year period, and options will have a term of 10 years from the date of grant. In addition, the 2019 Plan provides for automatic acceleration of vesting for options granted to non-employee directors upon a change of control of the Company.

The Amended 2010 Plan and the 2019 Plan are referred to collectively as the “Plans.”

The expense relating to stock options is recognized on a straight-line basis over the requisite service period, usually the vesting period, based on the grant-date fair value. The unamortized compensation cost, as of ~~March 31,~~September 30, 2021, was $0.1 million related to stock options and is expected to be recognized as expense over a weighted-average period of approximately ~~1.25~~0.9 years. The expense related to restricted stock units (RSUs) is generally recognized over a three-year

vesting period and is based on the fair value of the underlying stock on the dates of grant. The unamortized compensation cost, as of ~~March 31,~~September 30, 2021, was ~~$0.2~~$0.4 million related to RSUs and is expected to be recognized as expense over a weighted-average period of approximately ~~0.5~~0.7 years.

For the three and nine months ended ~~March 31,~~September 30, 2021 and 2020, there were no0 excess tax benefits associated with the exercise of stock options due to the Company’s historical loss positions.

There were no0 stock options granted during the ~~three~~nine months ended ~~March 31,~~September 30, 2021 and 2020.

The term of all incentive stock options granted to a person who, at the time of grant, owns stock representing more than 10% of the voting power of all classes of the Company’s stock may not exceed five years. The exercise price of stock options granted under the 2019 Plan must be at least equal to the fair market value of the shares on the date of grant. Generally, options granted under the 2019 Plan will vest over a three to four-year period and have a term of 10 years from the date of grant. In addition, the 2019 Plan provides for automatic acceleration of vesting for options granted to non-employee directors upon a change of control of the Company.

The following table summarizes the activity in the shares available for grant under the Plans during the ~~three~~nine months ended ~~March 31,~~September 30, 2021 (in thousands, except exercise price):

				Options outstanding							Options outstanding
						Weighted							Weighted
	Shares					Average		Shares					Average
	Available			Number of		Exercise		Available			Number of		Exercise
	for Grant			Shares		Prices		for Grant			Shares		Prices
Balance as of January 1, 2021		81			159	$	10.82		81			159	$	10.82
RSUs granted		(10	)		—		—		(10	)		—		—
Balance as of March 31, 2021		71			159	$	10.82		71			159	$	10.82
RSUs granted									(59	)		—		—
Balance as of June 30, 2021									12			159	$	10.82
RSUs granted									0			—		—
Balance as of September 30, 2021									12			159	$	10.82

A summary of ~~RSU~~RSUs activity under the Plans is presented below (in thousands, except for fair value):

				Weighted					Weighted
				Average					Average
	Number of			Grant-Date		Number of			Grant-Date
	Shares			Fair Value		Shares			Fair Value
Non-vested shares as of January 1, 2021		65		$	3.48		65		$	3.48
Granted		10		$	3.25		10		$	3.25
Vested		(17	)	$	3.78		(17	)	$	3.78
Non-vested shares as of March 31, 2021		58		$	3.35		58		$	3.35
Granted							59		$	6.70
Vested							(2	)	$	3.11
Non-vested shares as of June 30, 2021							115		$	5.08
Vested							(20	)	$	3.49
Cancelled							(1	)	$	4.55
Non-vested shares as of September 30, 2021							94		$	5.43

The fair value of the ~~RSU~~RSUs granted during the ~~three~~nine months ended ~~March 31,~~September 30, 2021 was ~~$32,500.~~

~~The total intrinsic value of the RSUs outstanding as of March 31, 2021 was $0.2~~$0.5 million.

The following table summarizes significant ranges of outstanding and exercisable options as of ~~March 31,~~September 30, 2021 (in thousands, except contractual life and exercise price):

	Options Outstanding						Options Exercisable						Options Outstanding						Options Exercisable
			Weighted												Weighted
			Average												Average
			Remaining		Weighted				Weighted						Remaining		Weighted				Weighted
			Contractual		Average				Average		Aggregate				Contractual		Average				Average		Aggregate
	Number		Life		Exercise		Number		Exercise		Intrinsic		Number		Life		Exercise		Number		Exercise		Intrinsic
Range of Exercise Price	Outstanding		(in Years)		Price		Exercisable		Price		value		Outstanding		(in Years)		Price		Exercisable		Price		value
$1.57 - $14.99		143		8.01	$	2.62		79	$	2.88	$	185		143		7.51	$	2.62		101	$	2.80	$	219
$15.00 - $25.59		8		2.49	$	15.00		8	$	15.00	$	—		8		1.99	$	15.00		8	$	15.00	$	—
$25.60 - $143.99		2		3.11	$	41.81		2	$	41.81	$	—		2		2.60	$	41.81		2	$	41.81	$	—
$144.00 - $409.99		5		5.40	$	144.00		5	$	144.00	$	—		5		4.90	$	144.00		5	$	144.00	$	—
$410.00 - $924.00		1		3.94	$	430.64		1	$	430.64	$	—		1		3.44	$	430.64		1	$	430.64	$	—
$1.57 - $924.00		159		8.04	$	10.82		95	$	16.55	$	185		159		7.05	$	10.82		117	$	13.91	$	219

There ~~were no~~was 0 stock options exercised during the ~~three~~nine months ended ~~March 31,~~September 30, 2021 orand 2020.

In February 2021, the Company completed a registered direct offering of securities under an effective registration statement filed with the SEC pursuant to the Securities Act of 1933, as amended. In the offering, the Company sold 1,487,601 shares of common stock at a price of $5.00 per share to institutional investors. Net proceeds of the offering, after placement agent and other fees and expenses paid by the Company, were approximately $6.8 million.

In June 2021, the Company completed a registered direct offering of securities under an effective registration statement filed with the SEC pursuant to the Securities Act of 1933, as amended. In the offering, the Company sold 1,818,181 shares of common stock at a price of $7.15 per share to institutional investors. Net proceeds of the offering, after placement agent and other fees and expenses paid by the Company, were approximately $12.0 million.

During the ~~three~~nine months ended ~~March 31,~~September 30, 2021, the Company received a total of ~~$2,478,461~~$4,189,000 of proceeds from the exercise of ~~1,032,692~~1,744,769 warrants to purchase shares of common stock at a price of $2.40 per share.

In March 2016, the Company entered into a 10% Senior Secured Convertible Note Purchase Agreement (the Purchase Agreement) with the purchasers of $8,000,000 principal amount of 10% Senior Secured Convertible Notes due August 15, 2018 (the Notes), at par, in a private placement transaction effected pursuant to an exemption from the registration requirements under the Securities Act of 1933, as amended. Pursuant to amendments to the Notes and related documents in February and October 2018, the interest rate was reduced to 8%, the maturity date of the Notes was extended to August 15, 2023, and the optional conversion price was reduced from $170.00 of Note principal per share of common stock to $11.434 of Note principal per share of common stock.

In accordance with the October 2018 amendment to the Notes, the Company used $7.4 million of the proceeds from a public offering of securities effected in October 2018 to repay a portion of the Notes. Semi-annual interest payments have been made in each of February 2019, August 2019, February 2020 and August 2020 for approximately $78,000, $109,000, $112,000 and $122,000, respectively, in-kind with the issue of additional notes (Interest Notes) to the Purchasers. The Interest Notes have terms identical to the Notes.

~~The~~During the nine months ended September 30, 2021 the Company issued 42,672 shares of its common stock valued at $139,964 to the Note holder in settlement of ~~the~~ accrued interest ~~for the six month period ended February 15, 2021.~~of $123,066. The Company recorded a loss of $16,898 on this payment, which was recorded in other income in the condensed consolidated statements of operation.

In January and February 2021, a holder of warrants, who was also the holder of the Notes, exercised warrants to purchase 613,791 shares of the Company’s common stock at an exercise price of $2.40 per share for total proceeds of $1,473,098. The proceeds from the exercise of these warrants were used to repay a portion of the principal amount of the Notes.

In March 2021, the Company made a repayment of $1,554,173 in settlement of the outstanding principal amount of the Notes, and the Note holder’s security interest was terminated. The Company recorded a gain of $64,757 on the Note settlement, and the gain was recorded in other income in the condensed consolidated statements of operations.

On May 7, 2020, the Company entered into a Promissory Note with Wells Fargo Bank, N.A. (the Lender) in an aggregate principal amount of $579,330 (the PPP Note), pursuant to the Paycheck Protection Program (the PPP) under the CARES Act.

The term of the PPP Note is two years. Interest will accrue on the outstanding principal balance of the PPP Note at a fixed rate of 1.0%, which shall be deferred for the first ten months of the term of the PPP Note. Monthly payments will be due and payable beginning in March 2021 and continue each month thereafter until maturity of the PPP Note. The Company may prepay principal of the PPP Note at any time in any amount without penalty. The Agreement contains customary events of default relating to, among other things, payment defaults, breach of representations and warranties or provisions of the PPP Note. The occurrence of an event of default may result in the repayment of all amounts outstanding, collection of all amounts owing from the Company, and/or filing suit and obtaining judgment against the Company.

The Company applied to the Lender for forgiveness of the PPP Note, under the terms of the ~~PPP. No assurance is provided that~~PPP, and, in May 2021, obtained forgiveness for the ~~Company will obtain forgiveness~~full amount of the PPP Note and recognized the forgiven amount in ~~whole or~~other income in ~~part, but~~ the ~~Company believes it has used the proceeds in accordance with the PPP. If the PPP Note is not forgiven, principal payments will be due: $217,250 in 2021 and $362,080 in 2022.~~

The Company has ~~one~~1 lease, which is the lease for its corporate facility that expires in July 2022, that it accounts for under Accounting Standards Update No. 2016-02. The right-of-use asset and corresponding liability for the facility lease have been measured at the present value of the future minimum lease payments. The discount rate used to measure the lease asset and liability represents the interest rate on the Notes (8%). Lease expense is recognized on a straight-line basis over the lease term, and operating lease expense was approximately ~~$53,000~~$0.2 million and $0.2 million for the ~~three~~nine months ended ~~March 31, 2021.~~ September 30, 2021 and 2020, respectively. The Company does not have an option to extend the lease term beyond the current extension.

Future minimum payments under the facility operating lease at ~~March 31,~~September 30, 2021 ~~are~~were as follows (in thousands):

	Operating			Operating
Year ending December 31,	lease			lease
2021	$	155		$	52
2022		112			113
Total future lease payments		267			165
Less: imputed interest		(9	)		(2	)
Present value of lease liabilities	$	258		$	163

Supplemental cash flow information related to the operating lease was as follows (in thousands):

ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the accompanying condensed consolidated financial statements and notes included in this report. This Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which include, without limitation, statements about the market for our technology, our strategy, competition, expected financial performance and capital raising efforts, risks inherent in our ability to consummate the proposed business combination with Peraso Technologies, Inc., the impacts of COVID-19 on our business, and other aspects of our business identified in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission on March 18, 2021 and in other reports that we file from time to time with the Securities and Exchange Commission. Any statements about our business, financial results, financial condition and operations contained in this Form 10-Q that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “expects,” “intends,” “plans,” “projects” or similar expressions are intended to identify forward-looking statements. Our actual results could differ materially from those expressed or implied by these forward-looking statements as a result of various factors, including the risk factors described under Item 1A of our annual report on Form 10-K for the year ended December 31, 2020and the risk factors described below under Item 1A of this Form 10-Q. We undertake no obligation to update publicly any forward-looking statements for any reason, except as required by law, even as new information becomes available or events occur in the future.

Our strategy and primary business objective is to be a profitable, intellectual property-rich, fabless semiconductor company offering integrated circuits, or ICs, and related software, firmware and intellectual property, or IP, that deliver unparalleled memory bandwidth and access rate performance for high-performance data processing in cloud networking, communications, security appliances, video, test and monitoring, and data center systems. Our solutions deliver time-to-market, performance, power, area and economic benefits for system original equipment manufacturers, or OEMs. Our primary product line is marketed under the Accelerator Engine name and comprises our Bandwidth Engine and Programmable HyperSpeed Engine IC products, which integrate our proprietary, 1T-SRAM high-density embedded memory and a highly-efficient serial interface protocol resulting in a monolithic memory IC solution optimized for memory bandwidth and transaction access performance. Our second-generation Bandwidth Engine, or Bandwidth Engine 2, products are expected to be our primary revenue source through at least ~~2021,~~2023, and we expect these products to continue to generate significant revenue thereafter. As we are not developing new IC products, from a product development perspective, we continue to leverage our current technologies and core competencies to expand our product offerings without incurring significant additional R&D expenses. We are developing our Virtual Accelerator Engine, or VAE, ~~product line consisting~~IP solutions which consist of software, firmware and other IP available for license. This product line will include multiple function accelerator platform products, which target specific application functions and will use a common software interface to allow performance scalability over multiple hardware environments. These function accelerator platform products are hardware agnostic and operate with or without one of our Accelerator Engine ICs. This software-defined, hardware-accelerated platform architecture utilizes an internally developed graphical memory engine architecture to provide flexible data classification and analysis capability. We believe the technology will generate new opportunities that require less up-front architectural changes by system designers and provide a scalable performance roadmap of options using our Accelerator Engine ICs. Despite our limited new IC product development efforts, we believe our current hardware and software/firmware product portfolio positions us for future growth and profitability.

We incurred net losses of approximately ~~$1.4~~$4.3 million for the ~~three~~nine months ended ~~March 31,~~September 30, 2021 and $3.8 million and $2.6 million for the years ended December 31, 2020 and 2019, respectively, and had an accumulated deficit of approximately ~~$244.0~~$246.9 million as of ~~March 31,~~September 30, 2021. These and prior year losses have resulted in significant negative cash flows for almost a decade and have necessitated that we raise substantial amounts of additional capital during this period. To date, we have primarily financed our operations through multiple offerings of common stock to investors and affiliates, as well as asset sale transactions and one offering of convertible notes.

We may continue to incur operating losses and will need to increase revenues substantially beyond levels that we have attained in the past in order to generate sustainable operating profit and sufficient cash flows to continue doing business without raising additional capital from time to time.

On September 14, 2021, we and our newly formed subsidiaries, 2864552 Ontario Inc. (Callco) and 2864555 Ontario Inc. (Canco), both corporations existing under the laws of the province of Ontario, entered into an Arrangement Agreement (the Agreement) with Peraso Technologies Inc., a corporation existing under the laws of the province of Ontario (Peraso). Under the Agreement, we, indirectly through Canco, are to acquire all of the issued and outstanding common shares of Peraso (Peraso Shares), including those Peraso Shares to be issued in connection with the conversion or exchange of secured convertible debentures of Peraso and common share purchase warrants of Peraso, as applicable, by way of a statutory plan of arrangement (the Arrangement) under the Business Corporations Act (Ontario) (the OBCA), on and subject to the terms and conditions of the Agreement

The Agreement provides that the Peraso stockholders may elect to receive either shares of our common stock or shares of the capital stock of Canco (the Exchangeable Shares) in exchange for such holder’s Peraso Shares, in each case based on an exchange ratio (the Exchange Ratio) to be determined based on the number of Peraso Shares and shares of our common stock outstanding as of immediately prior to the effective time of the Arrangement (the Effective Time). Pursuant to the terms of the Agreement, at the Effective Time, we shall hold an aggregate of 1,815,445 Exchangeable Shares and Common Stock (collectively, the Earnout Shares). Such Earnout Shares shall be escrowed pursuant to the terms of an escrow agreement on a pro rata basis from the aggregate consideration to be received by the Peraso stockholders, subject to the offset by us for any losses in accordance with the Agreement. Such Earnout Shares shall be released, subject to any offset claim, upon the satisfaction of the earlier of: (a) any date following the first anniversary of the Effective Time and prior to the third anniversary of the Effective Time where the volume weighted average price of our common stock for any 20 trading days within a period of 30 consecutive trading days is at least $8.57 per share, subject to adjustment for stock splits or other similar transaction; (b) the date of any sale of all or substantially all of the assets or shares of us; or (c) the date of any bankruptcy, insolvency, restructuring, receivership, administration, wind-up, liquidation, dissolution, or similar event involving us.

Following the Effective Time, each Exchangeable Share will be exchangeable by the holder for one share of common stock (subject to customary adjustments for stock splits or other reorganizations). In addition, we may require all outstanding Exchangeable Shares to be exchanged upon the occurrence of certain events and at any time following the seventh anniversary of the closing of the Arrangement. While outstanding, holders of Exchangeable Shares will be entitled to cast votes on matters for which holders of our common stock are entitled to vote and will be entitled to receive dividends economically equivalent to the dividends declared by us with respect to our common stock. Eligibility to receive Exchangeable Shares will be subject to certain Canadian residency restrictions and tax statuses.

The Agreement also provides that Peraso stock options, which are exercisable for Peraso Shares, will be replaced with an option to acquire common stock to be issued by us in consideration for cancellation of the Peraso options and exercisable for shares of our common stock after the Effective Time, in each case with adjustments based on the Exchange Ratio. The exact number of shares of common stock that will be issued pursuant to the Arrangement will be determined at the Effective Time in accordance with the Exchange Ratio.

Immediately following the Effective Time, based on the Exchange Ratio, the former stockholders of Peraso are anticipated to own approximately 61% of the economic and voting interest of the combined company with our current stockholders holding the remaining 39% economic and voting interest, as calculated on a fully-diluted basis and including the Earnout Shares.

The consummation of the Arrangement is subject to certain closing conditions precedent, including both our and Peraso’s stockholders approval of the Agreement and transactions contemplated therein; the order of the Ontario Superior Court of Justice (Commercial List) granted pursuant to Section 182(5) of the Business Corporations Act (Ontario); all regulatory approvals; the continuing listing of our common stock on the Nasdaq Capital Market; and other customary closing conditions.

Effective Time does not occur on or before November 30, 2021, subject to certain automatic extensions. The Agreement may also be terminated by either party, if the respective stockholders’ approval is not obtained, in the event of material adverse effect, or a superior proposal in connection with an alternative acquisition. The Agreement subjects the parties to certain termination payment obligations. If the Agreement is terminated because of the failure to obtain stockholders’ approval, the party that failed to obtain such approval will be obligated to pay a fee of $750,000 to the other party. If the Agreement is terminated by either party as a result of obtaining a superior proposal from a third party, breach of non-solicitation covenants of the Agreement, or because either party’s board of directors fails to unanimously recommend to proceed with the Arrangement or withdraws its recommendation, the breaching party will be required to pay a termination fee of $3,500,000.

The global outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency by the U.S. government in March 2020. This has negatively affected the U.S. and global economy, disrupted global supply chains, significantly restricted travel and transportation, resulted in mandated closures and orders to “shelter-in-place” and created significant disruption of the financial markets. The full extent of the COVID-19 impact on our operational and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions taken by the U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of our control, and cannot be predicted.

In March 2020, Santa Clara County in California, where we are based, issued a ”shelter-in-place” order (the Order) that was effective through the first quarter of 2021. We have been complying with the Order and have minimized business activities at our San Jose headquarters facility (our only facility) since March 2020. We have implemented a teleworking policy for our employees and contractors to reduce on-site activity at our facility. The Order impacted our ability to produce and ship our IC products in the second half of March 2020, as certain of our vendors in the San Francisco Bay Area closed in accordance with the Order. In April 2020, we resumed shipments of our IC products, as we and our vendors are supporting shipment of components for critical infrastructure, as defined by the federal government; however, our employees are still generally restricted from visiting our customer and vendor sites, and we are unable to conduct certain product testing and development activities.

We remain diligent in continuing to identify and manage risks to our business given the changing uncertainties related to COVID-19. The ultimate impact of the Covid-19 pandemic on our business and results of operations is uncertain and difficult to predict, and we are closely monitoring impacts, especially to customer programs and our supply chain. We expect that the impacts of the COVID-19 pandemic will continue to have a negative impact on our revenues for the remainder of 2021, although we are not in a position to quantify such impacts. In addition, we have and continue to experience shortages and longer lead times for certain components used to manufacture our IC products. While we believe that our operations personnel are currently in a position to meet expected customer demand levels in the coming quarters, we recognize that unpredictable events could create difficulties in the months ahead. We may not be able to address these difficulties in a timely manner, which could negatively impact our business, results of operations, financial condition and cash flows.

The continued spread of COVID-19 has also led to disruption and volatility in the global capital markets. During the ~~quarter~~nine months ended ~~March 31,~~September 30, 2021, we were able to raise additional capital and make full repayment of our convertible notes payable (see discussion below under Liquidityand in Notes 8 and 9 to the condensed consolidated financial statements included in Part I, Item I of this Form 10-Q), however, if we need to raise additional capital to support operations in the future, we may be unable to access the capital markets and additional capital may only be available to us on terms that could be significantly detrimental to our existing stockholders and to our business.

For additional information on risks that could impact our future results, please refer to “Risk Factors” in Part II, Item 1A. of this quarterly report on Form 10-Q.

Product. Product revenue is generally recognized at the time of shipment to our customers. An estimated allowance may be recorded, at the time of shipment, for future returns and other charges against revenue consistent with the terms of sale.

Royalty and other. Our licensing contracts typically provide for royalties based on the licensee’s use of our memory technology in their currently shipping commercial products. We estimate royalty revenue in the period in which the licensee uses the licensed technology. Payments are received in the following period.

The discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these condensed consolidated financial statements requires us to make certain estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. On an ongoing basis we make these estimates based on our historical experience and on assumptions that we consider reasonable under the circumstances. Actual results may differ from these estimates and reported results could differ under different assumptions or conditions. Our significant accounting policies and estimates are disclosed in Note 1 of the “Notes to Consolidated Financial Statements” in our annual report on Form 10-K for the year ended December 31, 2020. As of ~~March 31,~~September 30, 2021, there have been no material changes to our significant accounting policies and estimates.

	March 31,						Change				September 30,						Change
	2021			2020			2020 to 2021				2021			2020			2020 to 2021
	(dollar amounts in thousands)										(dollar amounts in thousands)
Product -three months ended	$	1,178		$	1,068		$	110	10	%	$	1,210		$	1,803		$	(593	)	(33	)%
Percentage of total net revenue		88	%		85	%						91	%		91	%
Product -nine months ended											$	3,405		$	4,550		$	(1,145	)	(25	)%
Percentage of total net revenue												89	%		88	%

Product revenue ~~increased~~decreased for the three and nine months ended ~~March 31,~~September 30, 2021 compared with the same period of 2020 primarily due to ~~higher~~lower sales of our Bandwidth Engine 2 ~~products, partially offset by decreases in our~~and LineSpeed ~~product sales.~~IC products.

	March 31,						Change					September 30,						Change
	2021			2020			2020 to 2021					2021			2020			2020 to 2021
	(dollar amounts in thousands)											(dollar amounts in thousands)
Royalty and other -three months ended	$	160		$	192		$	(32	)	(17	)%	$	127		$	168		$	(41	)	(24	)%
Percentage of total net revenue		12	%		15	%							9	%		9	%
Royalty and other -nine months ended												$	438		$	649		$	(211	)	(33	)%
Percentage of total net revenue													11	%		12	%

Royalty and other includes license, royalty and related revenues generated from licensing agreements. The decrease in royalty and other revenue for the three months ended ~~March 31,~~September 30, 2021 compared with the same period of 2020 was ~~primarily~~due to a decrease in legacy royalty revenues. The decrease in royalty and other revenue for the nine months ended September 30, 2021 compared with the same period of 2020 was due to a decrease in royalty ~~revenue for one licensee.~~revenues and $0.1 million of non-recurring license revenues recognized during the three months ended June 30, 2020.

	March 31,						Change					September 30,						Change
	2021			2020			2020 to 2021					2021			2020			2020 to 2021
	(dollar amounts in thousands)											(dollar amounts in thousands)
Cost of net revenue -three months ended	$	495		$	530		$	(35	)	(7	)%	$	376		$	677		$	(301	)	(44	)%
Percentage of total net revenue		37	%		42	%							28	%		34	%
Cost of net revenue -nine months ended												$	1,315		$	1,811		$	(496	)	(27	)%
Percentage of total net revenue													34	%		35	%

	March 31,						Change				September 30,						Change
	2021			2020			2020 to 2021				2021			2020			2020 to 2021
	(dollar amounts in thousands)										(dollar amounts in thousands)
Gross profit -three months ended	$	843		$	730		$	113	15	%	$	961		$	1,294		$	(333	)	(26	)%
Percentage of total net revenue		63	%		58	%						72	%		66	%
Gross profit -nine months ended											$	2,528		$	3,388		$	(860	)	(25	)%
Percentage of total net revenue												66	%		65	%

Cost of net revenue is primarily comprised of direct and indirect costs related to the sale of our IC products.

Cost of net revenue decreased for the three and nine months ended ~~March 31,~~September 30, 2021 when compared with the same ~~period~~periods in 2020, primarily due to decreased shipment volumes of our LineSpeed ~~product which was only partially offset by the increase of our~~and Bandwidth Engine ~~products that have lower production costs.~~IC products.

Gross profit ~~increased~~decreased for the three and nine months ended ~~March 31,~~September 30, 2021 compared with the same period of 2020 due to the ~~increase~~decrease in gross profit attributable to the ~~increases~~decreases in ~~product~~ revenues. ~~As a percentage of net revenue, gross profit~~

~~increased due to higher gross margins on our product sales and higher royalty and other revenue, which generally has no associated cost.~~

	March 31,						Change				September 30,						Change
	2021			2020			2020 to 2021				2021			2020			2020 to 2021
	(dollar amounts in thousands)										(dollar amounts in thousands)
Research and development -three months ended	$	1,159		$	961		$	198	21	%	$	1,281		$	972		$	309	32	%
Percentage of total net revenue		87	%		76	%						96	%		49	%
Research and development -nine months ended											$	3,662		$	2,918		$	744	25	%
Percentage of total net revenue												95	%		56	%

Our research and development expenses include costs related to the development of our IC products and VAE ~~IP products.~~IP. We expense research and development costs as they are incurred.

The increase for the three and nine months ended ~~March 31,~~September 30, 2021 compared with the same period of 2020 was primarily due to increases in personnel costs due to ~~new hires~~headcount increases and increases in consulting costs for development of our VAE ~~products.~~IP. We expect that total research and development expenses will increase in 2021 compared with 2020 as we incur increased development costs for our VAE ~~products.~~IP.

	March 31,						Change					September 30,						Change
	2021			2020			2020 to 2021					2021			2020			2020 to 2021
	(dollar amounts in thousands)											(dollar amounts in thousands)
SG&A -three months ended	$	1,071		$	1,135		$	(64	)	(6	)%	$	1,398		$	955		$	443	46	%
Percentage of total net revenue		80	%		90	%							105	%		48	%
SG&A -nine months ended												$	3,756		$	3,054		$	702	23	%
Percentage of total net revenue													98	%		59	%

Selling, general and administrative, or SG&A, expenses consist primarily of personnel and related overhead costs for sales, marketing, finance, human resources and general management.

The ~~decrease~~increase for the three and nine months ended ~~March 31,~~September 30, 2021 compared with the same period of 2020 was primarily due to ~~decreases~~increases in ~~professional services~~transaction costs related to the Arrangement with Peraso. Transaction costs incurred in connection with the Arrangement were $0.3 million and ~~facilities~~$0.7 million for the three and ~~travel costs, partially offset by increased legal and personnel costs.~~nine months ended September 30, 2021, respectively. We expect total SG&A expenses to remain relatively consistent for the remainder of 2021.

	March 31,						Change					September 30,						Change
	2021			2020			2020 to 2021					2021			2020			2020 to 2021
	(dollar amounts in thousands)											(dollar amounts in thousands)
Interest expense - three months ended	$	30		$	54		$	(24	)	(44	)%	$	—		$	54		$	(54	)	(100	)%
Percentage of total net revenue		2	%		4	%							—			3	%
Interest expense - nine months ended												$	30		$	164		$	(134	)	(82	)%
Percentage of total net revenue													1	%		3	%

Interest expense consisted of interest expense on our senior secured convertible notes (the Notes). As of March 31, 2021, we had repaid the full remaining principal amount of the Notes and accrued interest. We do not expect to incur interest expense during the remainder of 2021. See Note 910 to the condensed consolidated financial statements included in this report for additional disclosure.

As of ~~March 31,~~September 30, 2021, we had cash, cash equivalents and ~~short-term~~ investments of ~~$11.1~~$21.2 million and working capital of ~~$10.9~~$18.6 million. We believe that cash generated from our liquidity sources will be sufficient to meet both our short-term and long-term working capital and capital expenditure needs for the foreseeable future.

Net cash used in operating activities was ~~$1.0~~$4.6 million for the first ~~three~~nine months of 2021, which primarily resulted from our net loss of ~~$1.4~~$4.3 million, ~~which was partially offset by $0.3~~adjusted for a $0.6 million of gains for debt extinguishment and $0.1 million in net changes in assets and liabilities, ~~and~~which was partially offset by non-cash charges of ~~$0.1~~$0.4 million. The changes in assets and liabilities primarily related to the timing of accounts receivable collections, purchases of inventory and other vendor payables and prepayments.

Net cash used in operating activities was ~~$0.7~~$1.6 million for the first ~~three~~nine months of 2020, which primarily resulted from our net loss of ~~$1.4~~$2.8 million, which was partially offset by ~~$0.5~~$0.7 million in net changes in assets and liabilities and non-cash charges of ~~$0.1~~$0.2 million of stock-based compensation, depreciation and amortization expenses and ~~$0.1~~$0.2 million of accrued interest. The changes in assets and liabilities primarily related to the timing of ~~customer~~accounts receivable collections, and inventory and other vendor payables and prepayments.

Net cash used in investing activities of ~~$1.6~~$11.4 million for the ~~three~~nine months ended ~~March 31,~~September 30, 2021 represented $12.7 million in purchases of short and long-term investments, partially offset by $1.3 million in proceeds from maturities of short-term investments. Net cash provided by investing activities for the ~~three~~nine months ended ~~March 31,~~September 30, 2020 was mainly due to the proceeds from ~~the~~ maturities of short-term investments of $0.3 million.

Net cash provided by financing activities of ~~$6.3~~$19.9 million for the ~~three~~nine months ended ~~March 31,~~September 30, 2021 primarily consisted of $6.8 million and $12.0 million in net proceeds received from the registered direct ~~offering~~offerings of our common stock completed in February 2021 and ~~$2.5~~June 2021, respectively, and $4.2 million of proceeds from the exercise of warrants to purchase shares of common stock at a price of $2.40 per share. We used approximately $3 million of these proceeds to repay in full the outstanding balance of ~~our senior secured convertible notes. There were minimal~~the Notes.

Net cash ~~flows used in~~provided by financing activities ~~during~~of $2.2 million for the ~~three~~nine months ended ~~March 31, 2020.~~September 30, 2020 primarily consisted of $1.6 million in net proceeds received from the sale of common stock in a registered direct offering of securities completed in April 2020 and $0.6 million of proceeds from an unsecured loan under the Paycheck Protection Program.

Our future liquidity and capital requirements are expected to vary from quarter-to-quarter, depending on numerous factors, including:

Our primary need for liquidity is to fund working capital requirements of our ~~businesses,~~business and capital expenditures, ~~and~~as well as for general corporate purposes. We expect our cash expenditures to exceed receipts in 2021, as our revenues will not be sufficient to offset our working capital requirements. During the nine months ended September 30, 2021, we completed two registered direct offerings of our common stock that generated net proceeds of approximately $18.8 million. Also, during 2021, we received proceeds of $4.2 million from the exercise of common stock warrants. During the three months ended March 31, 2021, we ~~received proceeds of $2.5 million from~~repaid in full the ~~exercise of common stock warrants, and we used $1.5 million of these proceeds to repay a portion of the~~outstanding principal balance of our ~~senior secured convertible notes. In February 2021, we completed a registered direct offering of securities that generated net proceeds of approximately $6.8 million.~~Notes. In May 2020, we entered into a Promissory Note with Wells Fargo Bank, N.A. (the Lender) in an aggregate principal amount of approximately $0.6 million (the PPP Note), pursuant to the Paycheck Protection Program (the PPP) under the CARES Act. In March 2021, we applied for forgiveness of the PPP Note under the terms of the ~~PPP. No assurance is provided that~~PPP, and, in May 2021, we ~~will obtain~~obtained forgiveness of the full amount of the PPP Note from the Lender. As a result of these activities, at September 30, 2021, we had approximately $21.2 million in ~~whole or in part, but we believe we have used the proceeds in accordance with the PPP.~~cash and investments and no debt.

In the event that additional financing is required through sales of our equity securities, our stockholders would suffer dilution of their equity ownership, and we may be required to accept other terms that could be significantly detrimental to our existing stockholders and to our business. If we engage in debt financing, we may be required to accept terms that restrict our ability to incur additional indebtedness, prohibit us from paying dividends, repurchasing our stock or making investments, and force us to maintain specified liquidity or other ratios, any of which could be significantly detrimental

to our business, operating results and financial condition. If we need additional capital and cannot raise it on acceptable terms, we may not be able to, among other things:

Our failure to do any of these things could seriously harm our ability to execute our business strategy and may force us to curtail our existing operations or research and development plans.

We do not maintain any off-balance sheet arrangements or obligations that are reasonably likely to have a material current or future effect on our financial condition, results of operations, liquidity or capital resources.

Disclosure Controls and Procedures. Our management is responsible for establishing and maintaining adequate internal control over our financial reporting. Because of inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934. Based on this evaluation, our management concluded that, as of ~~March 31,~~September 30, 2021, our disclosure controls and procedures were effective.

Changes in Internal Control over Financial Reporting. During the ~~three~~nine months ended ~~March 31,~~September 30, 2021, there was no change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

The discussion of legal matters in Note 4 of the Notes to Condensed Consolidated Financial Statements included in Part I, Item 1 of this report under the heading “Legal Matters” is incorporated by reference in response to this Part II, Item 1.

We face many significant risks in our business, some of which are unknown to us and not presently foreseen. These risks could have a material adverse impact on our business, financial condition and results of operations in the future. Except as set forth below, there have been no material changes with respect to the risk factors disclosed under Item 1A of our annual report on Form 10-K for the year ended December 31, 2020, which we filed with the SEC on March 18, 2021.

Our planned Arrangement with Peraso in accordance with the terms of Agreement as well as the Agreement itself presents considerable uncertainties and risks, including:

Furthermore, there can be no assurance that regulators, including foreign regulatory authorities will not impose conditions, terms, obligations or restrictions, or that such conditions, terms, obligations or restrictions will not have the effect of delaying completion of the Arrangement or imposing additional material costs on or materially limiting the revenues of the combined company following the Arrangement. In addition, we can provide no assurance that any such conditions, obligations or restrictions will not result in the delay or abandonment of the Arrangement.For additional information on the risks associated with our proposed Arrangement with Peraso please review the risks beginning on page 49 of the definitive proxy statement filed with the Securities and Exchange Commission on October 18, 2021, which risks are incorporated by reference herein and included as Exhibit 99.1 to this report.

The full effects of COVID-19 and other potential future public health crises, epidemics, pandemics or similar events are uncertain and could have a material and adverse effect on our business, financial condition, operating results and cash flows.

The global outbreak of the coronavirus disease 2019, ~~(COVID-19)~~or COVID-19, was declared a pandemic by the World Health Organization and a national emergency by the U.S. government in March 2020. This has negatively affected the world economy, disrupted global supply chains, significantly restricted travel and transportation, resulted in mandated closures and orders to “shelter-in-place” and created significant disruption of the financial markets. The extent of the impact on our operational and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions ~~taken by~~ U.S. and foreign government agencies continue to take to prevent disease spread, all of which are uncertain, out of our control and cannot be predicted.

In accordance with applicable U.S. governmental ordinances generally exempting essential businesses and/or critical infrastructure workforces from mandated closures and orders to “shelter-in-place,” we are operating in support of essential products and services, subject to limitations and requirements in applicable state and county orders. We have been complying with county and state orders and have implemented a ~~work-from-home~~teleworking policy for our employees and contractors and significantly minimized the number of employees who visit our office. Since the outbreak of COVID-19, while we have experienced increased lead times for wafers, substrates and assembly services, and, more recently, shortages, we have experienced minimal impact on our production operations and, to date, have been able to satisfy all customer purchase orders timely. However, a facility closure, work slowdowns or temporary stoppage at one of our ~~production vendors~~manufacturing suppliers could occur, which could have a longer-term impact and could delay our ~~deliveries to customers~~production and ability to conduct ~~business. For example, the “shelter-in-place” orders impacted~~business and negatively impact our ~~ability to produce~~business, financial condition, operating results and ~~ship our IC products in the second half of March, as certain of our vendors in the San Francisco Bay Area closed in accordance with governmental orders.~~cash flows.

If ~~significant portions of~~ our workforce ~~are~~is unable to work effectively, including because of illness, quarantines, absenteeism, government actions, facility closures, travel restrictions or other restrictions in connection with the COVID-19 pandemic, our operations will be negatively impacted. We may be unable to ~~market~~produce and sell our IC products, and our costs may increase as a result of the COVID-19 outbreak. The impacts could worsen if there is an extended duration of any COVID-19 outbreak or a resurgence of COVID-19 infection in affected regions after they have begun to experience improvement.

We rely on other companies to provide raw materials and to perform manufacturing and testing of our products. An extended period of global supply chain disruption, including extended lead times to purchase materials or procure testing services caused by the response to COVID-19 could impact our ability to ship our products. For example, we have already experienced longer lead times for certain components used to manufacture our IC products. If we are not able to implement alternatives or other mitigations, product deliveries would be adversely impacted and negatively impact our business, financial condition, operating results and cash flows.

As a result of COVID-19, we could see delays in new customer product programs and reduced customer demand for our products, which would adversely affect our revenues, financial performance and cash flows, and could result in asset impairments. Delays in transaction processing, including payment processing, by our customers, many of whom are teleworking, could also affect our revenues and cash flows, and current limitations on travel to customers could impact orders and business prospects. Limitations on government operations can also impact regulatory approvals that may be necessary for us to operate our business.

The continued spread of COVID-19 has also led to disruption and volatility in the global capital markets. WeAlthough we were ~~recently~~ able to ~~raise additional~~access the capital ~~however, if we need to raise additional capital to support operations~~markets in ~~the future,~~connection with our February 2021 and June 2021 registered direct offerings, we may be unable to access the capital markets, and additional capital may only be available to us on terms that could be significantly detrimental to our existing stockholders and to our business.

~~ITEM 2. Unregistered Sales~~We are working with our stakeholders, including customers, suppliers and employees, to address the impact of ~~Equity Securities~~this global pandemic. We continue to monitor the situation, to assess further possible implications to our business, supply chain and ~~Use~~customers, and to take actions in an effort to mitigate adverse consequences. Should such disruption continue for an extended period of ~~Proceeds~~

~~On February 1, 2021,~~time, or if and when the ~~Company issued 42,672 shares~~pandemic ends, the resumption of ~~its common stock valued at $139,964 to the holder~~normal business operations may be delayed or constrained by lingering effects of the ~~Senior Secured Convertible Notes due August 15, 2023 in settlement~~pandemic (including limitations imposed by governmental authorities on our ability to return to normal operating practices). These effects, alone or taken together, could have a material adverse impact on our business, results of the accrued interest for the six month period ended February 15, 2021. Such shares were issued in a private placement transaction that was exempt from the registration requirements under the Securities Act pursuant to Section 4(a)(2) of the Securities Act.operations or financial condition.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Delaware		77-0291941
(State or other jurisdiction		(I.R.S. Employer
of Incorporation or organization)		Identification Number)

PART I —	FINANCIAL INFORMATION	3

Item 1.	Financial Statements (Unaudited):	3

	Condensed Consolidated Balance Sheets as of ~~March 31,~~September 30, 2021 and December 31, 2020	3

	Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended ~~March 31,~~September 30, 2021 and 2020	4

	Condensed Consolidated Statements of Stockholders’ Equity for the three and nine months ended ~~March 31,~~September 30, 2021 and 2020	5

	Condensed Consolidated Statements of Cash Flows for the ~~three~~nine months ended ~~March 31,~~September 30, 2021 and 2020	6

	Notes to Condensed Consolidated Financial Statements	7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	1618

Item 4.	Controls and Procedures	2125

PART II —	OTHER INFORMATION	2125

Item 1.	Legal Proceedings	2125

Item 1A.	Risk Factors	21

~~Item 2.~~	~~Unregistered Sales of Equity Securities and Use of Proceeds~~	2225

Item 6.	Exhibits	2327

	Signatures	2428

(a)	Exhibits

	~~10.22(1)~~2.1 (1)	~~Form of Securities Purchase~~Arrangement Agreement with Peraso Technologies, Inc.
	2.2 (2)	First Amending Agreement dated ~~February 17,~~October 21, 2021
	10.2310.1	~~First Amendment to Executive Severance and Change-In-Control Policy~~Waiver Letter dated ~~April 28,~~August 2, 2021
	10.2 (3)	Form of Peraso Technologies, Inc. Voting Agreement
	10.3 (4)	Form of MoSys, Inc. Voting Agreement
	31.1*	Rule 13a-14 certification
	31.2*	Rule 13a-14 certification
	32.1**	Section 1350 certifications
	99.1*	Risk factors in connection with the Arrangement
	101*	The following financial information from MoSys, Inc.’s quarterly report on Form 10-Q for the period ended ~~March 31,~~September 30, 2021, filed with the SEC on ~~May 13,~~November 12, 2021, formatted in Inline Extensible Business Reporting Language ~~(XBRL)~~(Inline XBRL): (i) the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for the three and nine months ended ~~March 31,~~September 30, 2021 and 2020, (ii) the Condensed Consolidated Balance Sheets as of ~~March 31,~~September 30, 2021 and December 31, 2020, (iii) the Condensed Consolidated Statements of Changes in Stockholders’ Equity for the three and nine months ended ~~March 31,~~September 30, 2021 and 2020, (iv) the Condensed Consolidated Statements of Cash Flows for the ~~three~~nine months ended ~~March 31,~~September 30, 2021 and 2020, and (v) Notes to Condensed Consolidated Financial Statements.
	104*	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

	(1)	Incorporated by reference to Exhibit 2.1 to Form 8-K filed by the Company on September 15, 2021 (Commission File No. 000-32929)
	(2)	Incorporated by reference to Exhibit 2.1 to Form 8-K filed by the Company on October 22, 2021 (Commission File No. 000-32929)
	(3)	Incorporated by reference to Exhibit 10.1 to Form 8-K filed by the Company on ~~February 17,~~September 15, 2021 (Commission File No. ~~000-32929~~000-32929)
	(4)	Incorporated by reference to Exhibit 10.2 to Form 8-K filed by the Company on September 15, 2021 (Commission File No. 000-32929)


Dated: ~~May 13,~~November 12, 2021		MOSYS, INC.

	By:	/s/ Daniel Lewis
		Daniel Lewis
		President and Chief Executive Officer (Principal Executive Officer)

	By:	/s/ James W. Sullivan
		James W. Sullivan
		Vice President of Finance and Chief Financial Officer
		(Principal Financial and Accounting Officer)

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
Emerging growth company	☐

	December 31, 2020
			Unrealized		Unrealized		Fair
	Cost		Gains		Losses		Value
Cash and cash equivalents	$	5,889	$	—	$	—	$	5,889